<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" nameag="viewport"/>
<title>Non-Hodgkins Lymphoma</title>
<script src="https://cdn.tailwindcss.com"></script>
<script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
<script src="https://cdn.jsdelivr.net/npm/canvas-confetti@1.6.0/dist/confetti.browser.min.js"></script>
<style>
        /* Custom styles for enhanced aesthetics and responsiveness */
        .option-btn {
            transition: all 0.3s ease;
            box-shadow: 0 2px 4px rgba(0, 0, 0, 0.1);
        }
        .option-btn:hover, .option-btn:active {
            transform: scale(1.02);
            box-shadow: 0 4px 8px rgba(0, 0, 0, 0.2);
        }
        .option-btn.selected {
            background-color: #3b82f6;
            color: white;
        }
        .marked {
            background-color: #fef08a;
        }
        .progress-bar {
            transition: width 0.5s ease-in-out;
            background: linear-gradient(to right, #3b82f6, #22c55e);
            box-shadow: 0 2px 4px rgba(0, 0, 0, 0.2);
            animation: pulse 2s infinite;
        }
        @keyframes pulse {
            0% { opacity: 1; }
            50% { opacity: 0.8; }
            100% { opacity: 1; }
        }
        .question-nav-btn, .result-nav-btn-grid {
            width: 40px;
            height: 40px;
            display: flex;
            align-items: center;
            justify-content: center;
            border-radius: 8px;
            font-size: 16px;
            touch-action: manipulation;
            transition: all 0.2s ease;
        }
        .question-nav-btn:hover, .question-nav-btn:active, .result-nav-btn-grid:hover, .result-nav-btn-grid:active {
            transform: scale(1.05);
        }
        .answered {
            background-color: #22c55e;
            color: white;
        }
        .unanswered {
            background-color: #e5e7eb;
        }
        .marked-nav {
            border: 2px solid #fef08a;
        }
        .video-container, .audio-container {
            display: none;
            position: relative;
        }
        .video-container.active, .audio-container.active {
            display: block;
            animation: fadeIn 0.5s ease-in;
        }
        @keyframes fadeIn {
            from { opacity: 0; }
            to { opacity: 1; }
        }
        .section-transition {
            transition: opacity 0.3s ease;
        }
        .section-transition.hidden {
            opacity: 0;
            pointer-events: none;
        }
        .result-nav {
            display: flex;
            justify-content: space-between;
            align-items: center;
            margin-top: 1rem;
        }
        .result-nav-btn {
            background-color: #4b5563;
            color: white;
            padding: 0.5rem 1rem;
            border-radius: 8px;
            transition: all 0.2s ease;
        }
        .result-nav-btn:hover, .result-nav-btn:active {
            background-color: #374151;
            transform: scale(1.05);
        }
        .result-nav-btn:disabled {
            background-color: #d1d5db;
            cursor: not-allowed;
        }
        .error-message {
            color: #dc2626;
            font-weight: bold;
            margin-top: 1rem;
        }
        /* Mobile-specific adjustments */
        @media (max-width: 640px) {
            .question-nav-btn, .result-nav-btn-grid {
                width: 38px;
                height: 38px;
                font-size: 14px;
            }
            .nav-panel, .results-nav-panel {
                width: 100%;
                max-width: 100%;
                overscroll-behavior: contain;
            }
            .option-btn {
                padding: 12px;
                font-size: 14px;
            }
            .header-text {
                font-size: 1.5rem;
            }
            .subheader-text {
                font-size: 0.875rem;
            }
            .button-group, .result-nav {
                flex-direction: column;
                gap: 0.5rem;
            }
            .result-nav-btn {
                width: 100%;
                text-align: center;
            }
        }
        /* Dark mode styles */
        .dark .bg-gray-100 {
            background-color: #1f2937;
        }
        .dark .bg-white {
            background-color: #374151;
        }
        .dark .text-gray-700 {
            color: #d1d5db;
        }
        .dark .text-gray-800 {
            color: #e5e7eb;
        }
        .dark .bg-gray-200 {
            background-color: #4b5563;
        }
        .dark .border {
            border-color: #4b5563;
        }
        .dark .bg-blue-500 {
            background-color: #2563eb;
        }
        .dark .hover\:bg-blue-600:hover {
            background-color: #1d4ed8;
        }
        .dark .bg-yellow-300 {
            background-color: #b45309;
            color: white;
        }
        .dark .hover\:bg-yellow-400:hover {
            background-color: #92400e;
        }
        .dark .bg-green-500 {
            background-color: #15803d;
        }
        .dark .hover\:bg-green-600:hover {
            background-color: #166534;
        }
        .dark .bg-gray-500 {
            background-color: #4b5563;
        }
        .dark .hover\:bg-gray-600:hover {
            background-color: #374151;
        }
        .dark .result-nav-btn, .dark .result-nav-btn-grid {
            background-color: #2563eb;
        }
        .dark .result-nav-btn:hover, .dark .result-nav-btn:active, .dark .result-nav-btn-grid:hover, .dark .result-nav-btn-grid:active {
            background-color: #1d4ed8;
        }
        .dark .result-nav-btn:disabled, .dark .result-nav-btn-grid:disabled {
            background-color: #4b5563;
        }
        .video-placeholder {
            width: 400px;
            height: 300px;
            background-color: #f0f0f0;
            display: flex;
            align-items: center;
            justify-content: center;
            cursor: pointer;
            margin-top: 10px;
            border-radius: 8px;
            border: 1px solid #ccc;
        }
        .play-icon {
            font-size: 40px;
            color: #007bff;
        }
        .video-loading {
            position: absolute;
            top: 50%;
            left: 50%;
            transform: translate(-50%, -50%);
            border: 4px solid #f3f3f3;
            border-top: 4px solid #3b82f6;
            border-radius: 50%;
            width: 40px;
            height: 40px;
            animation: spin 1s linear infinite;
        }
        @keyframes spin {
            0% { transform: translate(-50%, -50%) rotate(0deg); }
            100% { transform: translate(-50%, -50%) rotate(360deg); }
        }
    </style>

<script>
    // --- GEMINI AUTO-CAPTURE LISTENER ---
    // This function runs immediately after the quiz determines an answer is INCORRECT.
    function captureMistake(questionIndex, questionsData) {
        try {
            const item = questionsData[questionIndex];
            // Use the question text as a unique, stable identifier
            const uniqueId = 'srs_quiz_' + btoa(item.text.substring(0, 50)).replace(/=/g, ''); 

            // 1. Clean and simplify the explanation for storage
            let explanationText = item.explanation || item.correct_answer || "No explanation provided.";
            
            // Strip complex HTML (images, lists) and boilerplate text
            explanationText = explanationText.replace(/<img[^>]*>/g, "[IMAGE]").trim(); // Replace images with placeholder
            explanationText = explanationText.replace(/<p><strong>Ans\. [A-Z]\).*/i, "").trim(); // Remove the repeated Answer line
            explanationText = explanationText.replace(/<p><strong>Educational Objective:<\/strong>.*?<\/p>/gs, "").trim(); // Remove EO block
            explanationText = explanationText.replace(/@dams_new_robot/g, "");
            explanationText = explanationText.replace(/<\/?[^>]+(>|$)/g, " ").trim(); // Final strip of remaining tags

            // 2. Prepare card data
            const cardData = {
                text: item.text,
                answer: item.correct_answer,
                explanation: explanationText.substring(0, 500), // Keep explanations short
                nextReview: 0, // Due immediately
                reviews: 0,
                source: document.title.split('-')[0].trim() || 'Quiz'
            };

            // 3. Save to Local Storage (SRS Bank)
            localStorage.setItem(uniqueId, JSON.stringify(cardData));
            
            console.log(`üß† Captured Mistake #${questionIndex + 1} from ${document.title}`);

        } catch (e) {
            console.error("SRS Capture Failed:", e);
        }
    }
    // --- END GEMINI AUTO-CAPTURE LISTENER ---
</script>

</head>
<body class="bg-gray-100 font-sans transition-colors duration-300 min-h-screen overflow-y-auto">
<!-- Header Section -->
<header class="bg-blue-600 text-white p-4 shadow-lg">
<div class="container mx-auto">
<h1 class="text-2xl md:text-3xl font-bold header-text">Non-Hodgkins Lymphoma</h1>
<p class="mt-2 text-sm md:text-base subheader-text">
                11 Questions | 11 Total Marks | 21 min Duration | ~114.55 sec/question
            </p>
<button class="mt-2 bg-gray-200 text-gray-800 px-3 py-1 rounded-lg hover:bg-gray-300 transition dark:bg-gray-600 dark:text-white" id="theme-toggle">
                Toggle Dark Mode
            </button>
</div>
</header>
<!-- Instructions Section -->
<section class="container mx-auto p-4 md:p-6 section-transition" id="instructions">
<div class="bg-white rounded-lg shadow-md p-5 md:p-8 md:p-5 md:p-8 min-h-screen md:min-h-0 md:rounded-lg md:shadow-md rounded-none shadow-none flex flex-col justify-between">
<h2 class="text-xl font-semibold mb-4">Instructions</h2>
<ul class="list-disc list-inside space-y-2 text-gray-700">
<li>This test contains 11 multiple choice questions.</li>
<li>Each question has only one correct answer.</li>
<li>You will have 21 minutes to complete the test.</li>
<li>Click or tap on an option to select your answer.</li>
<li>Use the "Mark for Review" button to revisit questions.</li>
<li>Navigate using Previous/Next buttons or the Questions Navigation panel.</li>
<li>Click "Submit" to finish and view results.</li>
<li>The test will auto-submit when time runs out.</li>
</ul>
<div class="mt-6 flex space-x-4 button-group md:flex-row flex-col">
<button class="bg-blue-500 text-white px-6 py-2 rounded-lg hover:bg-blue-600 transition" id="start-test">Start Test</button>


</div>
<div class="error-message hidden" id="error-message"></div>
</div>
</section>
<!-- Quiz Section -->
<section class="container mx-auto p-4 md:p-6 hidden section-transition" id="quiz">
<div class="bg-white rounded-lg shadow-md p-5 md:p-8 md:p-5 md:p-8 min-h-screen md:min-h-0 md:rounded-lg md:shadow-md rounded-none shadow-none flex flex-col justify-between">
<!-- Progress Bar -->
<div class="w-full bg-gray-200 rounded-full h-3 mb-4">
<div class="progress-bar h-3 rounded-full" id="progress-bar" style="width: 0%"></div>
</div>
<!-- Question Header -->
<div class="flex flex-col md:flex-row justify-between items-center mb-4">
<h2 class="text-lg font-semibold" id="question-number">Question <span>1</span> of 11</h2>
<p class="text-lg font-semibold mt-2 md:mt-0" id="timer">Time Remaining: <span>00:00</span></p>
</div>
<!-- Question Content -->
<div class="mb-6" id="question-content">
<p class="text-gray-800 mb-4" id="question-text"></p>
<div class="flex flex-wrap gap-4 mb-4" id="question-images"></div>
<div class="space-y-3" id="options"></div>
</div>
<!-- Navigation Buttons -->
<div class="flex flex-col md:flex-row justify-between items-center gap-2 md:gap-4">
<button class="bg-gray-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-gray-400 transition w-full md:w-auto" disabled="" id="previous-btn">Previous</button>
<button class="bg-yellow-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-yellow-400 transition w-full md:w-auto" id="mark-review">Mark for Review</button>
<button class="bg-blue-500 text-white px-4 py-2 rounded-lg hover:bg-blue-600 transition w-full md:w-auto" id="next-btn">Next</button>
<button class="bg-gray-500 text-white px-4 py-2 rounded-lg hover:bg-gray-600 transition w-full md:w-auto" id="nav-toggle">Questions Navigation</button>
<button class="bg-green-500 text-white px-4 py-2 rounded-lg hover:bg-blue-600 transition w-full md:w-auto" id="submit-test">Submit Test</button>
</div>
</div>
</section>
<!-- Results Section -->
<section class="container mx-auto p-4 md:p-6 hidden section-transition" id="results">
<div class="bg-white rounded-lg shadow-md p-5 md:p-8 md:p-5 md:p-8 min-h-screen md:min-h-0 md:rounded-lg md:shadow-md rounded-none shadow-none flex flex-col justify-between">
<h2 class="text-2xl font-semibold mb-4">Non-Hodgkins Lymphoma - Results</h2>
<div class="grid grid-cols-1 md:grid-cols-2 gap-4 mb-6">
<p><strong>Correct:</strong> <span id="correct-count">0</span></p>
<p><strong>Wrong:</strong> <span id="wrong-count">0</span></p>
<p><strong>Unanswered:</strong> <span id="unanswered-count">0</span></p>
<p><strong>Marked for Review:</strong> <span id="marked-count">0</span></p>
</div>
<h3 class="text-lg font-semibold mb-4" id="result-question-number">Question <span>1</span> of 11</h3>
<div class="space-y-6" id="results-content"></div>
<div class="result-nav">
<button aria-label="Previous question result" class="result-nav-btn" disabled="" id="prev-result">Previous</button>
<button aria-label="Toggle results navigation panel" class="result-nav-btn" id="results-nav-toggle">Results Navigation</button>
<button aria-label="Next question result" class="result-nav-btn" id="next-result">Next</button>
</div>
<div class="mt-6 flex space-x-4 button-group md:flex-row flex-col">
<button class="bg-blue-500 text-white px-6 py-2 rounded-lg hover:bg-blue-600 transition" id="take-again">Take Again</button>
<button class="bg-gray-500 text-white px-6 py-2 rounded-lg hover:bg-gray-600 transition" id="review-test">Review Test</button>
</div>
</div>
</section>
<!-- Exit Confirmation Modal -->
<div class="fixed inset-0 bg-black bg-opacity-50 flex items-center justify-center hidden" id="exit-modal">
<div class="bg-white rounded-lg p-6 max-w-sm w-full">
<h2 class="text-xl font-semibold mb-4">Leave Test?</h2>
<p class="text-gray-700 mb-4">Your progress will be lost if you leave this page. Are you sure you want to exit?</p>
<div class="flex justify-end space-x-4">
<button class="bg-gray-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-gray-400 transition" id="continue-test">No, Continue</button>
<button class="bg-red-500 text-white px-4 py-2 rounded-lg hover:bg-red-600 transition" id="exit-test">Yes, Exit</button>
</div>
</div>
</div>
<!-- Submit Confirmation Modal -->
<div class="fixed inset-0 bg-black bg-opacity-50 flex items-center justify-center hidden" id="submit-modal">
<div class="bg-white rounded-lg p-6 max-w-sm w-full">
<h2 class="text-xl font-semibold mb-4">Confirm Submission</h2>
<p class="text-gray-700 mb-2">You have attempted <span id="attempted-count">0</span> of 11 questions.</p>
<p class="text-gray-700 mb-4"><span id="unattempted-count">0</span> questions are unattempted.</p>
<div class="flex justify-end space-x-4">
<button class="bg-gray-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-gray-400 transition" id="cancel-submit">Cancel</button>
<button class="bg-green-500 text-white px-4 py-2 rounded-lg hover:bg-green-600 transition" id="confirm-submit">Submit Test</button>
</div>
</div>
</div>
<!-- Quiz Navigation Panel -->
<div class="fixed inset-y-0 right-0 nav-panel bg-white shadow-lg p-4 hidden overflow-y-auto" id="nav-panel">
<h2 class="text-lg font-semibold mb-4">Questions Navigation</h2>
<div class="mb-4">
<select class="w-full p-2 border rounded-lg text-gray-700" id="nav-filter">
<option value="all">All Questions</option>
<option value="answered">Answered</option>
<option value="unanswered">Unanswered</option>
<option value="marked">Marked for Review</option>
</select>
</div>
<div class="grid grid-cols-5 gap-2 md:gap-3" id="nav-grid"></div>
<button class="mt-4 bg-gray-500 text-white px-4 py-2 rounded-lg hover:bg-gray-600 transition w-full" id="close-nav">Close</button>
</div>
<!-- Results Navigation Panel -->
<div class="fixed inset-y-0 right-0 results-nav-panel bg-white shadow-lg p-4 hidden overflow-y-auto" id="results-nav-panel">
<h2 class="text-lg font-semibold mb-4">Results Navigation</h2>
<div class="mb-4">
<select class="w-full p-2 border rounded-lg text-gray-700" id="results-nav-filter">
<option value="all">All Questions</option>
<option value="answered">Answered</option>
<option value="unanswered">Unanswered</option>
<option value="marked">Marked for Review</option>
</select>
</div>
<div class="grid grid-cols-5 gap-2 md:gap-3" id="results-nav-grid"></div>
<button class="mt-4 bg-gray-500 text-white px-4 py-2 rounded-lg hover:bg-gray-600 transition w-full" id="close-results-nav">Close</button>
</div>
<!-- JavaScript Logic -->
<script>
        // Enable debug mode for detailed logging
        const DEBUG_MODE = true;

        // Log debug messages
        function debugLog(message) {
            if (DEBUG_MODE) {
                console.log(`[DEBUG] ${message}`);
            }
        }

        // Initialize questions with error handling
        let questions = [];
        let currentResultQuestion = 0; // State for current question in results
        try {
            debugLog("Attempting to parse questions_json");
            questions = [{"text": "Most Common extranodal site of Lymphoma in HIV is?", "options": [{"label": "A", "text": "CNS", "correct": true}, {"label": "B", "text": "GIT", "correct": false}, {"label": "C", "text": "Retroperitoneum", "correct": false}, {"label": "D", "text": "Mediastinum", "correct": false}], "correct_answer": "A. CNS", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>CNS Most common extranodal site for Lymphoma in: General population: GIT (stomach). HIV patients: CNS .</p>\n<p><strong>Highyeild:</strong></p><p>Lymphoma in HIV 90% of lymphomas in HIV are B cells in phenotype; more than half contain EBV DNA . Immunoblastic lymphomas account for 60% of the cases of lymphoma in patients with AIDS. Primary CNS lymphoma accounts for 20% of the cases of lymphoma in patients with HIV infection . The most common extranodal site involved in Lymphoma in HIV is the CNS, which is involved in one-third of all patients with lymphoma.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options:- Option: B. GIT. The most common extranodal site for Lymphoma in the general population . Option: C. Retroperitoneum. Incorrect . Option: D. Mediastinum. Incorrect .</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Neoplastic cells with multilobulated nuclei (cloverleaf or flower cells) are seen in-", "options": [{"label": "A", "text": "Diffuse large B cell lymphoma", "correct": false}, {"label": "B", "text": "Adult T cell leukaemia", "correct": true}, {"label": "C", "text": "Anaplastic large T cell lymphoma", "correct": false}, {"label": "D", "text": "Mycosis fungoides", "correct": false}], "correct_answer": "B. Adult T cell leukaemia", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Adult T cell leukaemia Adult T-Cell Leukaemia/Lymphoma This neoplasm of CD4+ T cells is only observed in adults infected by human T-cell leukaemia retrovirus type 1( HTLV-1 ) Common findings include skin lesions, generalized lymphadenopathy, hepatosplenomegaly, peripheral blood lymphocytosis, and hypercalcemia . Tumour cells with multilobulated nuclei (‚Äúcloverleaf‚Äù or ‚Äúflower‚Äù cells) . Most patients present with a rapidly progressive disease that is fatal within months to 1 year despite aggressive chemotherapy . Less commonly, the tumour involves only the skin and follows a much more indolent course, like that of mycosis fungoides</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options:- Option: A. Diffuse large B cell lymphoma. Shows a relatively large cell size and a diffuse pattern of growth . Option: C. Anaplastic large T cell lymphoma. Typically composed of large anaplastic cells, with horseshoe-shaped nuclei & voluminous cytoplasm (so-called hallmark cells ). Option: D. Mycosis fungoides. Neoplastic T cells, often have a cerebriform appearance due to marked infolding of the nuclear membrane.</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Gastric MALTomas may express all of the following except:", "options": [{"label": "A", "text": "CD5", "correct": true}, {"label": "B", "text": "CD19", "correct": false}, {"label": "C", "text": "CD20", "correct": false}, {"label": "D", "text": "CD43", "correct": false}], "correct_answer": "A. CD5", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>CD5 Expressed by Mantle zone lymphoma.</p>\n<p><strong>Highyeild:</strong></p><p>Marginal Zone Lymphoma: The category of marginal zone lymphomas encompasses a group of B-cell tumours that arise within lymph nodes, spleen, or extranodal tissues . Extranodal tumours were initially recognized at mucosal sites and are often referred to as mucosa-associated lymphoid tumours (or MALTomas) . In most cases, the tumour cells show evidence of somatic hypermutation and are considered to be of memory B-cell origin . It has three exceptional characteristics. They often arise within tissues involved by chronic inflammatory disorders of autoimmune or infectious etiology ; examples include the salivary gland in Sj√∂gren disease, the thyroid gland in Hashimoto thyroiditis, and the stomach in Helicobacter gastritis. They remain localized for prolonged periods , spreading systemically only late in their course. They may regress if the inciting agent (e.g., H. pylori) is eradicated . MALT lymphomas express B-cell antigens (CD19 and CD20) & monotypic surface Ig (IgM without IgD). MALTomas may be CD43+ but lack other small B-cell lymphoma markers (CD5, CD10, CD23 & cyclin D1).</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options:- Option: B. CD19. MALTomas are B cell tumours and thus express CD 19 (Pan B cell marker) . Option: C. CD20. MALTomas are B cell tumours and thus express CD 20 (Mature B cell marker) . Option: D. CD43. Expressed by MALTomas.</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "The Commonest site for extranodal lymphoma is-", "options": [{"label": "A", "text": "Liver", "correct": false}, {"label": "B", "text": "Stomach", "correct": true}, {"label": "C", "text": "Small intestine", "correct": false}, {"label": "D", "text": "Large intestine", "correct": false}], "correct_answer": "B. Stomach", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Stomach The commonest site for extranodal lymphoma is the Stomach The gastrointestinal tract is the most common site for extranodal NHL (10 to 15% of all NHL). The stomach accounts for 50% of gastrointestinal lymphomas 60% of gastric lymphoma are aggressive, usually DLBCL, while 40% are low-grade, usually MALT type.</p>\n<p><strong>Highyeild:</strong></p><p>Most common extranodal site for Lymphoma in: General population: GIT (stomach). HIV patients: CNS . Lymphoma in HIV 90% of lymphomas in HIV are B cells in phenotype; more than half contain EBV DNA centresunoblastic lymphomas accounting for 60% of the cases of lymphoma in patients with AIDS. Primary CNS lymphoma accounts for 20% of the cases of lymphoma in patients with HIV infection . The most common extranodal site involved in Lymphoma in HIV is the CNS, which is involved in one-third of all patients with lymphoma.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options:- Option: A. Liver. Incorrect . Option: C. Small intestine. Incorrect . Option: D. Large intestine. Incorrect .</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "‚ÄúSmudge cells‚Äù in the peripheral smear are characteristic of-", "options": [{"label": "A", "text": "Chronic myelogenous leukaemia", "correct": false}, {"label": "B", "text": "Chronic lymphocytic leukaemia", "correct": true}, {"label": "C", "text": "Acute myelogenous leukaemia", "correct": false}, {"label": "D", "text": "Acute lymphoblastic leukaemia", "correct": false}], "correct_answer": "B. Chronic lymphocytic leukaemia", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Chronic lymphocytic leukaemia ‚ÄúSmudge cells‚Äù</p>\n<p><strong>Highyeild:</strong></p><p>Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL): CLL is the most common leukaemia in adults in the Western world . The median age at diagnosis is 60 years , and there is a 2:1 male predominance . Microscopy: Lymph nodes are diffusely effaced by predominantly small lymphocytes called Pseudofollicular architecture with proliferation centres . Peripheral smear: Smudge cells Caused by a decrease in Vimentin May predict a good prognosis Seen mainly in CLL; Also have been reported in AML, CML, and ALL & the normal peripheral smear, but rare. Chronic lymphocytic leukemia. This peripheral blood smear is flooded with small lymphocytes with condensed chromatin and scant cytoplasm. A characteristic finding is the presence of disrupted tumor cells (smudge cells), two of which are present in this smear. A coexistent autoimmune hemolytic anemia (Chapter 14) explains the presence of spherocytes (hyperchromatic, round erythrocytes). A nucleated erythroid cell is present in the lower left-hand corner of the field. In this setting, circulating nucleated red cells could stem from premature release of progenitors in the face of severe anemia, marrow infiltration by tumor (leukoerythroblastosis), or both. Mutation: Chromosome 13q deletion Immunohistochemistry: CD5 +, CD23 +, CD19 +, CD 20+ Transformation to diffuse large B-cell lymphoma (DLBCL), is called Richter syndrome .</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options:- Option: A. Chronic myelogenous leukaemia. False, leukocytosis, shift to left and basophilia are seen . Option: C. Acute myelogenous leukaemia. False, Myeloblasts are seen. Option: D. Acute lymphoblastic leukaemia. False, Lymphoblasts are seen.</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A patient of 70 years, presented with generalized lymphadenopathy. WBC count was 20,000/mm3 and blood film showed >70% mature-looking lymphocytes. Next investigation that should be done:", "options": [{"label": "A", "text": "LN biopsy", "correct": false}, {"label": "B", "text": "Peripheral blood Immunophenotyping", "correct": true}, {"label": "C", "text": "Bone marrow aspiration", "correct": false}, {"label": "D", "text": "Peripheral blood cytogenetics", "correct": false}], "correct_answer": "B. Peripheral blood Immunophenotyping", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Peripheral blood Immunophenotyping In the given question, an elderly patient with generalized lymphadenopathy was found to have a WBC count of 20,000/mm3 and blood film showed >70% mature-looking lymphocytes i.e. Peripheral smear has been done and is showing leukocytosis, with mature lymphocytes . Most likely this is a case of Non-Hodgkin Lymphoma with spillover in the peripheral blood . (Microscopy of Hodgkin‚Äôs lymphoma shows Reed Sternberg cells in a reactive background). NHLs can be identified on the basis of immunophenotyping:</p>\n<p><strong>Highyeild:</strong></p><p>CLL: CD 5+, CD 23+, CD 200+ Follicular Lymphoma: CD 10+, CD 5- Mantle cell Lymphoma: CD 5+, CD 10-, CD 23- Marginal Cell Lymphoma: CD 5-, CD 10- Hence, the next investigation that should be done is the Immunophenotyping of Peripheral Blood Lymphocytes . REMEMBER: Whenever there‚Äôs a question suggestive of Lymphoma, the next investigation would be a peripheral smear to differentiate NHL from HL and for any characteristic cells, if a peripheral smear is given, then the next investigation would be Immunophenotyping/ Immunohistochemistry to know the CD markers to narrow down the diagnosis, next investigation would be cytogenetics to know mutation and lastly bone marrow aspiration or biopsy for the staging of lymphoma.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options:- Option: A. LN biopsy. False, LN biopsy will not help in narrowing the diagnosis. Option: C. Bone marrow aspiration. False, done after Cytogenetics to know to the stage. Option: D. Peripheral blood cytogenetics. False, done after immunophenotyping.</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "The marker for Lymphoma is:", "options": [{"label": "A", "text": "S-100", "correct": false}, {"label": "B", "text": "HMB-45", "correct": false}, {"label": "C", "text": "Leukocyte common antigen", "correct": true}, {"label": "D", "text": "Cytokeratin", "correct": false}], "correct_answer": "C. Leukocyte common antigen", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Leukocyte common antigen Since Lymphoma arises from mature leukocytes, Lymphoma cells are positive for Leukocyte common antigen (CD45) .</p>\n<p><strong>Highyeild:</strong></p><p>CD markers: Cells CD markers Immature CD34 Blast CD 34 Lymphoblast: TdT WBC CD 45 Myeloblast MPO, CD 13, 33, 117 Lymphoid ‚óè       B cells: CD19 , 20, 21, 22, 23, 24, CD 10, CD 79a, PAX 5 ‚óè       T cells: CD 3 , 1, 2, 4, 5, 6, 7, 8 ‚óè       NK cells: CD 16, 56 Monocytes CD 14, 64</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options:- Option: A. S-100. Marker for peripheral nerve sheath tumours . S-100 protein is positive in all benign Schwann cell tumours . Option: B. HMB-45. Marker for melanoma . Option: D. Cytokeratin. Marker for Carcinoma .</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "The international prognostic index for lymphomas includes the following prognostic factors, except:", "options": [{"label": "A", "text": "Stage of disease", "correct": false}, {"label": "B", "text": "Number of extra lymphatic sites involved", "correct": false}, {"label": "C", "text": "LDH", "correct": false}, {"label": "D", "text": "Hemoglobin and albumin", "correct": true}], "correct_answer": "D. Hemoglobin and albumin", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Hemoglobin and albumin International prognostic index for lymphomas do not include Hemoglobin and albumin</p>\n<p><strong>Highyeild:</strong></p><p>International Prognostic Index for NHL Five Clinical Risk Factors Age ‚â•60 years Serum lactate dehydrogenase levels elevated Performance status ‚â•2 (ECOG) or ‚â§70 (Karnofsky) Ann Arbor stage III or IV >1 site of extranodal involvement For Diffuse Large B-cell Lymphoma 0, 1 factor low risk 35% of cases; 5-year survival, 73% 2 factors low-intermediate risk 27% of cases; 5-year survival, 51% 3 factors high-intermediate risk 22% of cases; 5-year survival, 43% 4, 5 factors high risk 16% of cases; 5-year survival, 26% For Diffuse Large B-cell Lymphoma Treated With R-CHOP O factor = good 10% of cases; 4-year survival, 94% 1, 2 factors intermediate 45% of cases; 4-year survival, 80% 3, 4, 5 factors = poor 45% of cases; 4-year survival, 53% Abbreviations: ECOG, Eastern Cooperative Oncology Group; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options:- Option: A. Stage of disease. Correct . Option: B. Number of extra lymphatic sites involved. Correct . Option: C. LDH. Correct .</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "About Burkitt‚Äôs lymphoma, true is-", "options": [{"label": "A", "text": "CD34 + ve & Surface Ig +ve", "correct": false}, {"label": "B", "text": "CD34 + ve & Surface Ig -ve", "correct": false}, {"label": "C", "text": "CD34 - ve & Surface Ig -ve", "correct": false}, {"label": "D", "text": "CD34 - ve & Surface Ig +ve", "correct": true}], "correct_answer": "D. CD34 - ve & Surface Ig +ve", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>CD34 - ve & Surface Ig +ve In Burkitt Lymphoma CD34 - ve & Surface Ig +ve CD34 is positive in Hematopoietic stem cells Classical triad of Burkitt‚Äôs lymphoma: CD19 +ve, Surface Ig +ve and CD34 - ve</p>\n<p><strong>Highyeild:</strong></p><p>Burkitt Lymphoma: Burkitt‚Äôs has a male predominance and is typically seen in patients <35 years of age . In Burkitt lymphoma , the tumour has a high mitotic index, and numerous apoptotic cells, combined with benign macrophages. Macrophages have abundant clear cytoplasm: a characteristic ‚Äú starry sky‚Äù pattern seen in Lymph Node biopsy. Mutation: C-MYC on Chromosome 8. t ( 8 ;14), t (2; 8 ), t ( 8 ;22). IHC: CD 10 +, CD19+, CD20+, and BCL6+, surface IgM+ Burkitt‚Äôs Lymphoma is the most common cause of tumour lysis syndrome . The classification of Burkitt‚Äôs Lymphoma Endemic (in Africa) 80-90% association with EBV. Most common site: Mandible . Sporadic 20-30% association with EBV. Most common site: The ileocaecal region . HIV associated 30-40% association with EBV. Most common site: Lymph node .</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options:- Option: A. p53 gene mutation. Germline mutation causes Li Fraumeni syndrome . Option: B. RB gene mutation. The mutation causes Retinoblastoma . Option: C. Translocation involving BCR-ABL genes. Seen with CML , a history of the 50-60-year-old patient would be given with leukocytosis, shift to left and basophilia .</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Burkitt‚Äôs lymphoma is -", "options": [{"label": "A", "text": "B cell lymphoma", "correct": true}, {"label": "B", "text": "6;14 translocations", "correct": false}, {"label": "C", "text": "Cannot present as an abdominal mass", "correct": false}, {"label": "D", "text": "Radiotherapy is used in the treatment", "correct": false}], "correct_answer": "A. B cell lymphoma", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>B cell lymphoma Burkitt‚Äôs lymphoma is a B-cell lymphoma , which can present as an abdominal mass</p>\n<p><strong>Highyeild:</strong></p><p>Burkitt Lymphoma: Burkitt‚Äôs has a male predominance and is typically seen in patients <35 years of age . In Burkitt lymphoma , the tumour has a high mitotic index, and numerous apoptotic cells, combined with benign macrophages. Macrophages have abundant clear cytoplasm: a characteristic ‚Äú starry sky‚Äù pattern seen in Lymph Node biopsy. Mutation: C-MYC on Chromosome 8. t ( 8 ;14), t (2; 8 ), t ( 8 ;22). IHC: CD 10 +, CD19+, CD20+, and BCL6+, surface IgM+ Burkitt‚Äôs Lymphoma is the most common cause of tumour lysis syndrome . Classification of Burkitt‚Äôs Lymphoma Endemic (in Africa) 80-90% association with EBV. Most common site: Mandible . Sporadic 20-30% association with EBV. Most common site: The ileocaecal region . HIV associated 30-40% association with EBV. Most common site: Lymph node .</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options:- Option: B. 6;14 translocations. False, C-MYC on Chromosome 8. t ( 8 ;14), t (2; 8 ), t ( 8 ;22) seen. Option: C. Cannot present as an abdominal mass. False . Option: D. Radiotherapy is used in treatment. False, Burkitt lymphoma is very aggressive but responds well to intensive chemotherapy .</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "The most malignant form of NHL is -", "options": [{"label": "A", "text": "Diffuse large B-cell lymphoma", "correct": true}, {"label": "B", "text": "Small cell lymphocytic lymphoma", "correct": false}, {"label": "C", "text": "Follicular cleavage", "correct": false}, {"label": "D", "text": "Large cell follicular lymphoma", "correct": false}], "correct_answer": "A. Diffuse large B-cell lymphoma", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Diffuse large B-cell lymphoma Diffuse large B-cell lymphoma is the most aggressive lymphoma . Follicular lymphomas are low-grade and indolent.</p>\n<p><strong>Highyeild:</strong></p><p>Diffuse large B-cell lymphoma (DLBCL): A Most common type of Non-Hodgkin‚Äôs lymphoma ( NHLs ) in the world and India . Has the worst prognosis among NHLs . CD 19 +ve, CD 20 +ve, mostly surface IgM +ve and variable CD 6 and CD 10 positive. Cytogenetics: BCL6 translocation, t(14;18), MYC. Microscopy: The common features are a relatively large cell size (usually four to five times the diameter of a small lymphocyte) and a diffuse pattern of growth . More anaplastic tumours may contain multinucleated cells with large inclusion-like nucleoli that resemble Reed-Sternberg cells (the malignant cell of Hodgkin lymphoma). Clinical features: DLBCL typically presents as a rapidly enlarging mass at a nodal or extranodal site. It can arise virtually anywhere in the body. Waldeyer ring, the oropharyngeal lymphoid tissue that includes the tonsils and adenoids, is involved commonly. DLBCLs are aggressive tumours that are rapidly fatal without treatment . DLBCLs with MYC translocations have a worse prognosis than those without and may be better treated with chemotherapy regimens that are now standard for Burkitt lymphoma.</p>\n<p><strong>Random:</strong></p><p>Explanation for incorrect options:- Option: B. Small cell lymphocytic lymphoma. Incorrect . Option: C. Follicular cleavage. Incorrect . Option: D. Large cell follicular lymphoma. Incorrect .</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}];
            if (!Array.isArray(questions) || questions.length === 0) {
                throw new Error("Questions data is empty or invalid");
            }
            debugLog(`Successfully parsed ${questions.length} questions`);
        } catch (e) {
            console.error("Failed to parse questions_json:", e);
            document.getElementById(